ALKS — Alkermes plc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1520262 ·
Last close
$40.15
Market Cap
$6.74B
52W High
$55.67
52W Low
$27.00
ADV30
1,819,624
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 392,911,000 | 331,333,000 | -48,280,000 | -66,480,000 | 4,258,076,000 | 351,551,000 | 2,506,545,000 |
| Dec 2025 | 384,547,000 | 338,338,000 | 58,104,000 | 49,341,000 | 2,486,993,000 | 388,570,000 | 667,698,000 |
| Sep 2025 | 394,185,000 | 342,594,000 | 89,082,000 | 82,761,000 | 2,329,512,000 | 616,449,000 | 596,080,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$256,200,000
Investing CF
$-1,790,605,000
Financing CF
$1,486,151,000
CapEx
$-44,530,000
Dividends Paid
—
Buybacks
$-27,696,000
EPS Diluted TTM
$0.38
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-801,274,000
Inventory
$336,703,000
Receivables
$407,630,000
ST Investments
$160,311,000
EBIT TTM
$237,204,000
Pretax Income TTM
$204,035,000
Interest Exp TTM
$33,169,000
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,667,651,968
EBITDA
$284,932,000
Free Cash Flow
$153,381,376
Enterprise Value
$8,628,064,256
Total Cash
$656,577,024
Total Debt
$1,572,563,968
Shares Out
167,763,272
Trailing EPS
$0.38
Book Value
$10.79
ROE
3.9%
ROA
4.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,475,899,000 | 253,956,000 | 241,664,000 | 2,486,993,000 | 667,698,000 | 1,819,295,000 | 520,754,000 |
| Dec 2024 | 1,557,632,000 | 420,636,000 | 367,070,000 | 2,055,567,000 | 590,590,000 | 1,464,977,000 | 439,124,000 |
| Dec 2023 | 1,663,405,000 | 414,122,000 | 355,757,000 | 2,136,223,000 | 933,537,000 | 1,202,686,000 | 401,353,000 |
| Dec 2022 | 1,111,795,000 | -6,089,000 | -158,267,000 | 1,963,978,000 | 920,225,000 | 1,043,753,000 | 21,044,000 |
TTM Snapshot
Revenues TTM
$399,082,000
NetIncome TTM
$-105,686,000
OpCashFlow TTM
$0
Assets (Latest)
$1,797,227,000
Forward EPS
$1.83
Max Pain — expiry 2026-12-18
max pain strike: $30.00 · spot: $40.15 · call oi: 72 · put oi: 948
Expected Move to 2026-12-18:
±$9.71
(24.18%) —
implied range
$30.44 –
$49.86
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.79B | $98.56 | — |
| BLTE | BELITE BIO, INC | $6.68B | $165.93 | — |
| LQDA | Liquidia Corp | $6.59B | $73.67 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $7.14B | $20.50 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $6.26B | $314.10 | — |
News headlines (Yahoo Finance, 1h cache)
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
2026-09-26 03:59 · Yahoo
Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says
2026-09-22 15:39 · Yahoo
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
2026-09-22 15:15 · Yahoo
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
2026-09-22 14:17 · Yahoo
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
2026-09-21 20:15 · Yahoo
Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290
2026-09-21 12:41 · Yahoo
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
2026-09-21 11:00 · Yahoo
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
2026-09-10 11:00 · Yahoo
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
2026-08-29 19:00 · Yahoo
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
2026-08-24 22:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.